CN111939229A - Composition for resisting asthenopia and xerophthalmia and treating pseudomyopia and preparation method thereof - Google Patents
Composition for resisting asthenopia and xerophthalmia and treating pseudomyopia and preparation method thereof Download PDFInfo
- Publication number
- CN111939229A CN111939229A CN201910400841.4A CN201910400841A CN111939229A CN 111939229 A CN111939229 A CN 111939229A CN 201910400841 A CN201910400841 A CN 201910400841A CN 111939229 A CN111939229 A CN 111939229A
- Authority
- CN
- China
- Prior art keywords
- extract
- acid
- composition
- asthenopia
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a composition for resisting asthenopia and xerophthalmia and treating pseudomyopia and a preparation method thereof, wherein the composition comprises the following components: main active ingredients of the eye care product comprise Mongolian milkvetch root extract, salvia miltiorrhiza extract, mint extract, dendrobium officinale extract, chamomile extract, rhodiola rosea extract, retinol palmitate, additives and preparation excipients which are prepared into a usable form and are needed, and relates to the technical field of eye treatment products. According to the composition for resisting asthenopia and dry eye and treating pseudomyopia and the preparation method, a Mongolian astragalus extract, a salvia extract, a mint extract, a dendrobium officinale extract, a chamomile extract, a rhodiola rosea extract, retinol palmitate, an additive and preparation excipients which are prepared into a usable form are mixed according to a traditional Chinese medicine ingredient principle to prepare a compound, and the purpose of relieving asthenopia, dry eye and pseudomyopia is achieved by matching with a massage effect.
Description
Technical Field
The invention relates to the technical field of eye treatment objects, in particular to a composition for resisting asthenopia and xerophthalmia and treating pseudomyopia and a preparation method thereof.
Background
In recent years, with the rapid pace development of social life and the popularization of networks, televisions and computers, the eye-using time is obviously prolonged, severe asthenopia is easily caused, the dry eyes, myopia or presbyopia of adults are caused, and eye diseases such as cataract, glaucoma, retinal detachment and the like are accompanied by excessive eye-using; meanwhile, the myopia rate of the eyes (including pseudomyopia, semi-true myopia and true myopia) in teenagers is greatly increased, the trend of myopia onset aging is more severe, and the literature reports that: the red sage root is slightly warm in nature, bitter in taste, non-toxic, and has the effects of activating blood circulation to dissipate blood stasis, soothing nerves and calming heart, so the red sage root has the saying that the first taste of the red sage root is the same as the fourth taste; the chamomile is slightly cold in nature and sweet and bitter in taste, and has the effects of dispelling wind, removing heat, clearing liver and improving vision; radix astragali is sweet and warm, and has the effects of invigorating qi, consolidating exterior, healing sore and promoting granulation; the mint is pungent in flavor and cool in nature, and has the effects of dispelling wind and heat, clearing head and eyes, soothing liver and promoting qi circulation; the dendrobium officinale is sweet in taste and slightly cold in nature, and has the effects of benefiting stomach, promoting fluid production, nourishing yin and clearing heat; the rhodiola root is cold in nature and sweet and astringent in taste, and has the effects of tonifying qi, clearing away lung-heat, benefiting intelligence and nourishing heart; the combination of the medicines can achieve the effects of relieving visual fatigue, dry eye and no hypermetropia.
At present, the asthenopia is generally relieved by reasonably arranging the rest time or directly dropping eye drops, however, the existing work and study pressure is high, a large amount of idle time is difficult to exist, so that the symptom is difficult to relieve by reasonably arranging the rest time, and the effect is not obvious.
For pseudomyopia, many treatment methods are used, such as vision correction instruments, small-hole glasses, eye-glasses for vision and music, laser therapy, magnetic therapy, electrotherapy, acupuncture and moxibustion and other therapies are common, although various therapies have certain curative effect and are relieved to a certain extent, most curative effect is not consolidated, and no better method is available for treating myopia at present, so that the problems of prevention, treatment, consolidation and the like of myopia of teenagers are urgently needed to be solved as early as possible.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides a composition for resisting asthenopia and xerophthalmia and treating pseudomyopia and a preparation method thereof, and solves the problems of unobvious effect and large toxic and side effects in the existing products.
(II) technical scheme
In order to achieve the purpose, the invention is realized by the following technical scheme: a composition for resisting asthenopia and xerophthalmia and treating pseudomyopia comprises the following components: the main active ingredients of the composition comprise astragalus mongholicus extract, salvia miltiorrhiza extract, mint extract, dendrobium officinale extract, chamomile extract, rhodiola rosea extract, retinol palmitate, additives and preparation excipients required by preparation into a usable form.
A method for preparing a composition for resisting asthenopia and xerophthalmia and treating pseudomyopia comprises the following steps:
s1: weighing 0.2-20 parts of propylene glycol, 4-400 parts of glycerol, 0.5-50 parts of phenoxyethanol, 0.05-2 parts of retinol palmitate, 0.2-20 parts of ubiquinone, 0.1-10 parts of VE and 0.2-20 parts of VC, mixing, adding 600mL of water, stirring and dissolving;
s2: adding 0.1-10 parts of Mongolian radix astragali extract, 1-30 parts of ginseng extract, 0.5-15 parts of mint extract, 1-30 parts of dendrobium officinale extract, 1-30 parts of chamomile extract and 0.5-15 parts of rhodiola rosea extract, stirring and dissolving at the same time, continuously adding water to a constant volume of 1L, and uniformly mixing to obtain the compound composition aqueous solution.
Further, the additive mainly refers to an additive for forming a preparation, and may be an antioxidant, a preservative, a pH adjuster, a wetting agent, a humectant, a perfume, a pigment, and a mixture of two or more of the above.
Further, the antioxidant may be inorganic sulfide such as sodium bisulfite, sodium metabisulfite, organic sulfide such as thioglycerol, cysteine, enol such as ascorbic acid, ascorbic acid ester, ascorbate, isoascorbic acid ester, isoascorbate, ethylenediaminetetraacetic acid and salts thereof; can be phenols such as hydroquinone, gallic acid, propyl gallate, tocopherol, tocopheryl acetate, and amino such as glycine and phenylalanine; may be quinones, such as ubiquinone.
Further, the preservative can be ester preservatives, such as methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, benzyl parahydroxybenzoate and phenyl parahydroxybenzoate, alcohol preservatives, such as phenoxyethanol, ethanol, propylene glycol and benzyl alcohol, acid preservatives, such as benzoic acid and salts thereof, formic acid and salts thereof, propionic acid and salts thereof, gentisic acid and salts thereof, mercury preservatives, such as thimerosal, phenylmercuric acetate and phenylmercuric borate, quaternary ammonium preservatives, such as benzalkonium chloride and benzalkonium bromide, chlorhexidine acetate, chlorhexidine hydrochloride, chlorhexidine gluconate and chlorhexidine iodide.
Further, the pH adjusting agent may be an acid substance such as hydrochloric acid, acetic acid, lactic acid, citric acid, tartaric acid, caproic acid, adipic acid, malic acid, phosphoric acid, succinic acid, boric acid, and salts thereof, the pH adjusting agent may be a base substance such as ethanolamine, isopropylamine, sodium carbonate, sodium hydroxide, potassium hydroxide, and ammonia solution, and the pH adjusting agent may also be a buffer solution such as phosphate buffer, borate buffer, succinate buffer, and tartrate buffer.
Further, the wetting agent may be ethanol, glycerin, or surfactant, such as lecithin, polysorbate, polyoxyethylene alkyl ether, benzyl, polyoxyethylene castor oil; the humectant can be selected from polyalcohol, saccharide, ceramide, and collagen, such as hyaluronic acid, sodium hyaluronate, glycerol, propylene glycol, butanediol, sorbitol, polyethylene glycol, xylitol, polypropylene glycol, ceramide, collagen, mucopolysaccharide, chitin derivative, aloe, and Sargassum extract.
Further, the formulation excipients required for preparing a usable form may be excipients for solution type, suspension type, emulsion type and gel type formulations, and include solvents, solubilizers, solubilizing agents, suspending agents, stabilizers, emulsifiers, matrix materials.
Further, the solvent may be an aqueous solvent or an oily solvent, such as water and aqueous solutions, propylene glycol, glycerin, medicinal oils, and mixtures of two or more thereof; the solubilizer is mainly a surfactant; the cosolvent can be acid, alkali, organic solvent and a mixture of two or more of the acid, the alkali and the organic solvent; the suspending agent can be a surfactant, a thickening agent and a mixture of two or more of the surfactants and the thickening agent; the emulsifier can be a surfactant, a high molecular compound capable of reducing surface tension, solid powder capable of stabilizing an interfacial film and a mixture of two or more of the substances; the matrix material can be oily matrix, emulsion matrix or water-based matrix, the oily matrix comprises hydrocarbon matrix, oil and fat matrix, lipid matrix and organic silicon oxide polymer, such as lanolin, beeswax; the emulsion type matrix is divided into an oil-in-water type matrix and a water-in-oil type matrix; the water-soluble matrix is made of natural or synthetic high molecular water-soluble substances, such as polyalcohol, cellulose derivative, glycerol, and gelatin base.
(III) advantageous effects
The invention has the following beneficial effects:
(1) according to the composition for resisting asthenopia and dry eye and treating pseudomyopia and the preparation method, by adopting a traditional Chinese medicine ingredient principle, a Mongolian astragalus extract, a salvia miltiorrhiza extract, a mint extract, a dendrobium officinale extract, a chamomile extract, a rhodiola rosea extract, retinol palmitate, an additive and a preparation excipient which is prepared into a usable form are mixed to prepare a compound for treatment, and the aim of relieving asthenopia, dry eye and pseudomyopia is achieved by matching with a massage effect.
Of course, it is not necessary for any product to practice the invention to achieve all of the above-described advantages simultaneously
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the description of the present invention, it is to be understood that the terms "opening," "upper," "lower," "thickness," "top," "middle," "length," "inner," "peripheral," and the like are used in an orientation or positional relationship that is merely for convenience in describing and simplifying the description, and do not indicate or imply that the referenced component or element must have a particular orientation, be constructed and operated in a particular orientation, and thus should not be considered as limiting the present invention.
The embodiment of the invention provides a technical scheme that: a composition for resisting asthenopia and xerophthalmia and treating pseudomyopia comprises the following components: the main active ingredients of the composition comprise astragalus mongholicus extract, salvia miltiorrhiza extract, mint extract, dendrobium officinale extract, chamomile extract, rhodiola rosea extract, retinol palmitate, additives and preparation excipients required by preparation into a usable form.
A method for preparing a composition for resisting asthenopia and xerophthalmia and treating pseudomyopia comprises the following steps:
s1: weighing 0.2-20 parts of propylene glycol, 4-400 parts of glycerol, 0.5-50 parts of phenoxyethanol, 0.05-2 parts of retinol palmitate, 0.2-20 parts of ubiquinone, 0.1-10 parts of VE and 0.2-20 parts of VC, mixing, adding 600mL of water, stirring and dissolving;
s2: adding 0.1-10 parts of Mongolian radix astragali extract, 1-30 parts of ginseng extract, 0.5-15 parts of mint extract, 1-30 parts of dendrobium officinale extract, 1-30 parts of chamomile extract and 0.5-15 parts of rhodiola rosea extract, stirring and dissolving at the same time, continuously adding water to a constant volume of 1L, and uniformly mixing to obtain the compound composition aqueous solution.
The additive mainly refers to additive for preparation, and can be antioxidant, antiseptic, pH regulator, wetting agent, humectant, perfume, pigment, and mixture of above two or more substances.
The antioxidant can be inorganic sulfide such as sodium bisulfite and sodium pyrobisulfite, organic sulfide such as thioglycerol and cysteine, and enol such as ascorbic acid, ascorbic acid ester, ascorbate, isoascorbic acid, isoascorbate, ethylenediaminetetraacetic acid and its salt; can be phenols such as hydroquinone, gallic acid, propyl gallate, tocopherol, tocopheryl acetate, and amino such as glycine and phenylalanine; may be quinones, such as ubiquinone.
The preservative can be ester preservatives, such as methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzyl p-hydroxybenzoate and phenyl p-hydroxybenzoate, alcohol preservatives, such as phenoxyethanol, ethanol, propylene glycol and benzyl alcohol, acid preservatives, such as benzoic acid and salts thereof, formic acid and salts thereof, propionic acid and salts thereof and gentisic acid and salts thereof, mercury preservatives, such as thimerosal, phenylmercuric acetate and phenylmercuric borate, quaternary ammonium preservatives, such as benzalkonium chloride and benzalkonium bromide, chlorhexidine acetate, chlorhexidine hydrochloride, chlorhexidine gluconate and chlorhexidine iodide.
The pH regulator can be acids such as hydrochloric acid, acetic acid, lactic acid, citric acid, tartaric acid, caproic acid, adipic acid, malic acid, phosphoric acid, succinic acid, boric acid and salts thereof, alkali substances such as ethanolamine, isopropylamine, sodium carbonate, sodium hydroxide, potassium hydroxide and ammonia solution, and buffer solutions such as phosphate buffer, borate buffer, succinate buffer and tartrate buffer.
The wetting agent can be ethanol, glycerol, or surfactant such as lecithin, polysorbate, polyoxyethylene alkyl ether, benzyl, polyoxyethylene castor oil; the humectant can be selected from polyalcohol, saccharide, ceramide, and collagen, such as hyaluronic acid, sodium hyaluronate, glycerol, propylene glycol, butanediol, sorbitol, polyethylene glycol, xylitol, polypropylene glycol, ceramide, collagen, mucopolysaccharide, chitin derivative, aloe, and Sargassum extract.
The excipient for the preparation required to be prepared into a usable form can be an excipient for solution type, suspension type, emulsion type and gel type preparations, and comprises a solvent, a solubilizer, a cosolvent, a suspending agent, a stabilizer, an emulsifier and a matrix material.
The solvent can be aqueous solvent or oily solvent, such as water and aqueous solution, propylene glycol, glycerol, medicinal oil, and mixture of two or more thereof; the solubilizer is mainly a surfactant; the cosolvent can be acid, alkali, organic solvent and a mixture of two or more of the acid, the alkali and the organic solvent; the suspending agent can be a surfactant, a thickening agent and a mixture of two or more of the surfactants and the thickening agent; the emulsifier can be a surfactant, a high molecular compound capable of reducing surface tension, solid powder capable of stabilizing an interfacial film and a mixture of two or more of the substances; the matrix material can be oily matrix, emulsion matrix or water-based matrix, the oily matrix comprises hydrocarbon matrix, oil and fat matrix, lipid matrix and organic silicon oxide polymer, such as lanolin, beeswax; the emulsion type matrix is divided into an oil-in-water type matrix and a water-in-oil type matrix; the water-soluble matrix is made of natural or synthetic high molecular water-soluble substances, such as polyalcohol, cellulose derivative, glycerol, and gelatin base.
The prescription composition of the compound composition water solution is shown in the following table:
second embodiment
The preparation of the compound composition gel, the prescription composition of the compound composition gel is shown in the following table:
the preparation process comprises the following steps: weighing poloxamer-188 according to the prescription amount, and adding into 250ml of water for dissolving; respectively weighing the prescribed amounts of propylene glycol, glycerin, poloxamer, phenoxyethanol, sodium hyaluronate, retinol palmitate, ubiquinone, VC and VE, adding about 600mL of water, stirring for dissolving, then respectively adding the prescribed amounts of astragalus mongholicus extract, salvia miltiorrhiza extract, mint extract, dendrobium officinale extract, chamomile extract and rhodiola rosea extract into the solution, and stirring for dissolving; mixing the above liquids, adding water to constant volume of 1L, and mixing to obtain compound gel.
Third embodiment
The preparation of the compound composition nanoemulsion, the prescription composition of the compound composition nanoemulsion is shown as the following table:
the preparation process comprises the following steps: respectively weighing poloxamer 188 and tween 80 according to the prescription amount, adding into 650mL of water, dissolving and mixing uniformly, weighing Mongolian milkvetch root extract, salvia miltiorrhiza extract, mint extract, dendrobium officinale extract, chamomile extract and rhodiola rosea extract according to the prescription amount, adding into the solution, dissolving and mixing uniformly for later use;
taking another beaker, respectively weighing ethylparaben and phenoxyethanol according to the prescription amount, adding glycerol according to the prescription amount, dissolving and uniformly mixing, then adding the mixture into the solution containing the traditional Chinese medicine extract, stirring and uniformly mixing, and stirring at the temperature of 60 ℃ and the speed of 1000rpm for later use;
weighing the white oil, the Span80, the retinol palmitate, the ubiquinone and the VE according to the prescription amount, mixing, stirring and mixing uniformly, heating to 60 ℃, then slowly adding the mixture into the water solution containing the traditional Chinese medicine extract, the poloxamer, the tween, the ethylparaben, the phenoxyethanol, the glycerol and the like which is stirred at a high speed, adding the VC, continuously stirring for 20 minutes, adding water to fix the volume to 1L, and homogenizing (500bar for 5 cycles) to obtain the traditional Chinese medicine compound composition nanoemulsion.
Fourth embodiment
Guinea pig acute skin irritation test of compound composition:
the Chinese medicinal compound composition is subjected to skin acute irritation test, 5 guinea pigs are selected for each example, the test temperature is 20-24 deg.C, the relative humidity is 60-70%, the hair on both sides of the spinal column of the tested animal is cut off within 24h before the test, the hair removing range is 3cm x 3cm, and the smearing area is 2.5cm x 2.5 cm. Taking 0.5mL of a test sample to be smeared on one side of skin, smearing blank solvent water on the other side of the test sample as a control for 1 time every day, continuously smearing for 14 days, shearing hair before smearing each time from the second day, removing residual test substances by using water or a non-irritant solvent, observing results after one hour, and performing irritation reaction evaluation according to the regulation of cosmetic hygiene Specification (2007 edition), wherein the evaluation results are shown in the following table:
as can be seen from the results, no acute skin irritation was observed in any of the compound compositions prepared in examples 1 to 3.
Fifth embodiment
The effectiveness test and the human body irritation test of the compound composition for treating the pseudomyopia comprise the following steps:
firstly, a medication mode: the different preparation forms of the compound composition in the examples 1-3 are respectively sprayed with 3-5ml (examples 1 and 3) under the condition of eye closure or evenly coated with 3-5g (example 2) around the eyes, 8-12 layers of gauze pads are applied to the eyes for 20-30 minutes, and a common plastic film is applied to the outer layer to prevent the volatilization of the medicine. The treatment is 1-2 times per day, and 14 days are used as 1 treatment course.
II, treatment effect evaluation standard:
a. and (3) curing: the naked eye vision is improved and is recovered to more than 1.0;
b. the effect is shown: the vision improvement reaches more than three grids on the visual chart, and the diopter is reduced to be within 50 degrees or is reduced by 50-75 degrees;
c. the method has the following advantages: the vision is improved by 1-2 grids on the visual chart;
d. and (4) invalidation: the vision and diopter are not changed.
Thirdly, the treatment effect is as follows:
the therapeutic effect and irritation of different compound compositions are compared
From the results, compared with placebo, the various traditional Chinese medicine compound compositions prepared by the invention have obvious pseudomyopia treatment effect, and no obvious irritation is found at the medicine application part.
Sixth embodiment
The effectiveness test and the human body irritation test of the compound composition for treating the asthenopia and the xerophthalmia are as follows:
firstly, a medication mode: the different preparation forms of the compound composition in the examples 1-3 are respectively sprayed with 3-5ml (examples 1 and 3) under the condition of eye closure or evenly coated with 3-5g (example 2) around the eyes, 8-12 layers of gauze pads are applied to the eyes for 20-30 minutes, and a common plastic film is applied to the outer layer to prevent the volatilization of the medicine. The treatment is 1-2 times per day, and 14 days are used as 1 treatment course.
II, treatment effect evaluation standard:
a. the method has the following advantages: (1) the duration of the long-term vision is increased, and the temporary vision blur disappears; or (2) the symptoms of dry eyes, burning sensation, itching, distending pain and lacrimation disappear or are relieved; or (3) headache, dizziness, hypomnesis and insomnia disappear or are relieved;
b. and (4) invalidation: the above symptoms are not changed.
Thirdly, the treatment effect is as follows:
comparison of therapeutic effects and irritation of different compound compositions on asthenopia and xerophthalmia
From the results, compared with the placebo, the traditional Chinese medicine compound compositions prepared by the invention have obvious effects of treating or relieving visual fatigue and dry eye, and no obvious irritation is found at the application part.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
The preferred embodiments of the invention disclosed above are intended to be illustrative only. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. Obviously, many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and the practical application, to thereby enable others skilled in the art to best utilize the invention. The invention is limited only by the claims and their full scope and equivalents.
Claims (9)
1. A composition for resisting asthenopia and xerophthalmia and treating pseudomyopia is characterized in that: comprises the following components: the main active ingredients of the composition comprise astragalus mongholicus extract, salvia miltiorrhiza extract, mint extract, dendrobium officinale extract, chamomile extract, rhodiola rosea extract, retinol palmitate, additives and preparation excipients required by preparation into a usable form.
2. The method of claim 1 for preparing a composition for anti-asthenopia, dry eye and pseudomyopia treatment, wherein the composition comprises: the method comprises the following steps:
s1: weighing 0.2-20 parts of propylene glycol, 4-400 parts of glycerol, 0.5-50 parts of phenoxyethanol, 0.05-2 parts of retinol palmitate, 0.2-20 parts of ubiquinone, 0.1-10 parts of VE and 0.2-20 parts of VC, mixing, adding 600mL of water, stirring and dissolving;
s2: adding 0.1-10 parts of Mongolian radix astragali extract, 1-30 parts of ginseng extract, 0.5-15 parts of mint extract, 1-30 parts of dendrobium officinale extract, 1-30 parts of chamomile extract and 0.5-15 parts of rhodiola rosea extract, stirring and dissolving at the same time, continuously adding water to a constant volume of 1L, and uniformly mixing to obtain the compound composition aqueous solution.
3. The composition for the treatment of asthenopia, dry eye and pseudomyopia according to claim 1, wherein: the additive mainly refers to additive for preparation, and can be antioxidant, antiseptic, pH regulator, wetting agent, humectant, perfume, pigment, and mixture of above two or more substances.
4. The composition for anti-asthenopia, dry eye and pseudomyopia treatment according to claim 3, wherein: the antioxidant can be inorganic sulfide such as sodium bisulfite and sodium pyrobisulfite, organic sulfide such as thioglycerol and cysteine, and enol such as ascorbic acid, ascorbic acid ester, ascorbate, isoascorbic acid, isoascorbate, ethylenediaminetetraacetic acid and its salt; can be phenols such as hydroquinone, gallic acid, propyl gallate, tocopherol, tocopheryl acetate, and amino such as glycine and phenylalanine; may be quinones, such as ubiquinone.
5. The composition for anti-asthenopia, dry eye and pseudomyopia treatment according to claim 3, wherein: the preservative can be ester preservatives, such as methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzyl p-hydroxybenzoate and phenyl p-hydroxybenzoate, alcohol preservatives, such as phenoxyethanol, ethanol, propylene glycol and benzyl alcohol, acid preservatives, such as benzoic acid and salts thereof, formic acid and salts thereof, propionic acid and salts thereof and gentisic acid and salts thereof, mercury preservatives, such as thimerosal, phenylmercuric acetate and phenylmercuric borate, quaternary ammonium preservatives, such as benzalkonium chloride and benzalkonium bromide, chlorhexidine acetate, chlorhexidine hydrochloride, chlorhexidine gluconate and chlorhexidine iodide.
6. The composition for anti-asthenopia, dry eye and pseudomyopia treatment according to claim 3, wherein: the pH regulator can be acids such as hydrochloric acid, acetic acid, lactic acid, citric acid, tartaric acid, caproic acid, adipic acid, malic acid, phosphoric acid, succinic acid, boric acid and salts thereof, alkali substances such as ethanolamine, isopropylamine, sodium carbonate, sodium hydroxide, potassium hydroxide and ammonia solution, and buffer solutions such as phosphate buffer, borate buffer, succinate buffer and tartrate buffer.
7. The composition for anti-asthenopia, dry eye and pseudomyopia treatment according to claim 3, wherein: the wetting agent can be ethanol, glycerol, or surfactant such as lecithin, polysorbate, polyoxyethylene alkyl ether, benzyl, polyoxyethylene castor oil; the humectant can be selected from polyalcohol, saccharide, ceramide, and collagen, such as hyaluronic acid, sodium hyaluronate, glycerol, propylene glycol, butanediol, sorbitol, polyethylene glycol, xylitol, polypropylene glycol, ceramide, collagen, mucopolysaccharide, chitin derivative, aloe, and Sargassum extract.
8. The composition for the treatment of asthenopia, dry eye and pseudomyopia according to claim 1, wherein: the excipient for the preparation required to be prepared into a usable form can be an excipient for solution type, suspension type, emulsion type and gel type preparations, and comprises a solvent, a solubilizer, a cosolvent, a suspending agent, a stabilizer, an emulsifier and a matrix material.
9. The composition for the treatment of asthenopia, dry eye and pseudomyopia according to claim 8, wherein: the solvent can be aqueous solvent or oily solvent, such as water and aqueous solution, propylene glycol, glycerol, medicinal oil, and mixture of two or more thereof; the solubilizer is mainly a surfactant; the cosolvent can be acid, alkali, organic solvent and a mixture of two or more of the acid, the alkali and the organic solvent; the suspending agent can be a surfactant, a thickening agent and a mixture of two or more of the surfactants and the thickening agent; the emulsifier can be a surfactant, a high molecular compound capable of reducing surface tension, solid powder capable of stabilizing an interfacial film and a mixture of two or more of the substances; the matrix material can be oily matrix, emulsion matrix or water-based matrix, the oily matrix comprises hydrocarbon matrix, oil and fat matrix, lipid matrix and organic silicon oxide polymer, such as lanolin, beeswax; the emulsion type matrix is divided into an oil-in-water type matrix and a water-in-oil type matrix; the water-soluble matrix is made of natural or synthetic high molecular water-soluble substances, such as polyalcohol, cellulose derivative, glycerol, and gelatin base.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910400841.4A CN111939229A (en) | 2019-05-15 | 2019-05-15 | Composition for resisting asthenopia and xerophthalmia and treating pseudomyopia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910400841.4A CN111939229A (en) | 2019-05-15 | 2019-05-15 | Composition for resisting asthenopia and xerophthalmia and treating pseudomyopia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111939229A true CN111939229A (en) | 2020-11-17 |
Family
ID=73335744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910400841.4A Pending CN111939229A (en) | 2019-05-15 | 2019-05-15 | Composition for resisting asthenopia and xerophthalmia and treating pseudomyopia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111939229A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113648279A (en) * | 2021-09-26 | 2021-11-16 | 杨璐萌 | Compound dendrobium eye drops for treating xerophthalmia and preparation method thereof |
| CN114404142A (en) * | 2022-02-23 | 2022-04-29 | 天津富勤科技股份有限公司 | Spontaneous heating eye patch capable of generating neutral or weakly acidic steam |
| WO2024005627A1 (en) * | 2022-06-30 | 2024-01-04 | Centro De Retina Médica Y Quirúrgica, S.C. | Topical ophthalmic formulation containing peppermint leaf extract for use in human eyeball tissues |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655315A (en) * | 2013-12-03 | 2014-03-26 | 天津嘉氏堂科技有限公司 | Black eye removal eye mask and preparation method thereof |
| CN106267169A (en) * | 2015-06-25 | 2017-01-04 | 陈红梅 | A kind of formula of Herba Dendrobii eye paste |
| CN106798760A (en) * | 2017-03-23 | 2017-06-06 | 左水荣 | The ocular fluid and eye sticker of preventing and treating teenage pseudomyopia and alleviation adult's visual fatigue |
| CN108635368A (en) * | 2018-07-19 | 2018-10-12 | 南京润斛堂生物科技有限公司 | A kind of eye-drops preparations containing small molecule dendrobium polysaccharide and preparation method and application |
| CN108853353A (en) * | 2018-08-06 | 2018-11-23 | 北京朗之星生物科技有限公司 | Have effects that protect active compound, preparation method and its application of eyesight |
-
2019
- 2019-05-15 CN CN201910400841.4A patent/CN111939229A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655315A (en) * | 2013-12-03 | 2014-03-26 | 天津嘉氏堂科技有限公司 | Black eye removal eye mask and preparation method thereof |
| CN106267169A (en) * | 2015-06-25 | 2017-01-04 | 陈红梅 | A kind of formula of Herba Dendrobii eye paste |
| CN106798760A (en) * | 2017-03-23 | 2017-06-06 | 左水荣 | The ocular fluid and eye sticker of preventing and treating teenage pseudomyopia and alleviation adult's visual fatigue |
| CN108635368A (en) * | 2018-07-19 | 2018-10-12 | 南京润斛堂生物科技有限公司 | A kind of eye-drops preparations containing small molecule dendrobium polysaccharide and preparation method and application |
| CN108853353A (en) * | 2018-08-06 | 2018-11-23 | 北京朗之星生物科技有限公司 | Have effects that protect active compound, preparation method and its application of eyesight |
Non-Patent Citations (2)
| Title |
|---|
| 余有庆等主编: "《中药临床备要》", 30 June 2008, 甘肃文化出版社 * |
| 李勤等: "中西药联用治疗干眼病疗效观察 ", 《中国社区医师》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113648279A (en) * | 2021-09-26 | 2021-11-16 | 杨璐萌 | Compound dendrobium eye drops for treating xerophthalmia and preparation method thereof |
| CN114404142A (en) * | 2022-02-23 | 2022-04-29 | 天津富勤科技股份有限公司 | Spontaneous heating eye patch capable of generating neutral or weakly acidic steam |
| CN114404142B (en) * | 2022-02-23 | 2024-03-29 | 天津富勤科技股份有限公司 | Self-heating eye cover capable of generating neutral or weak acid steam |
| WO2024005627A1 (en) * | 2022-06-30 | 2024-01-04 | Centro De Retina Médica Y Quirúrgica, S.C. | Topical ophthalmic formulation containing peppermint leaf extract for use in human eyeball tissues |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6209777B2 (en) | Compositions and treatments for eye diseases and disorders | |
| JP4745608B2 (en) | Skin treatment using phosphoric acid derivatives of electron transfer agents | |
| CN111939229A (en) | Composition for resisting asthenopia and xerophthalmia and treating pseudomyopia and preparation method thereof | |
| PT1853303E (en) | Stabilized compositions for topical administration and methods of making same | |
| CN105902418A (en) | Imitated sebum matrix, external preparation including imitated sebum matrix and application thereof | |
| BR0307126B1 (en) | Use of purslane to treat facial wrinkles | |
| JP2024016022A (en) | Cannabinoid dosing regime for dermatitis and inflammatory skin conditions | |
| JP2020529392A (en) | Compositions for the prevention or treatment of scars | |
| HU218921B (en) | Topical use of anorganic salt of stroncium (ii) for producing pharmaceutical compositions for treating neurogen skin-diseases | |
| WO2013050959A1 (en) | Composition for the treatment of skin lesions | |
| JP5871921B2 (en) | New use of hesperetin | |
| RU2530629C2 (en) | Drug-induced lipoatrophy for cosmetic purposes | |
| CN108542883A (en) | A kind of spray that eye is applied outside | |
| HU218946B (en) | Topical use of anorganic salts of stroncium (ii) for producing pharmaceutical compositions for treating eye pruritis, eye- and eyelid-acs and eye-and eyelid dysaesthesia | |
| CN108815175A (en) | A kind of spray that eye is applied outside | |
| KR20110050450A (en) | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid | |
| CA2620242A1 (en) | Topical soothing bruise healing preparation | |
| CN117298073B (en) | Transdermal drug delivery pharmaceutical composition for treating xerophthalmia | |
| CN114099551B (en) | Asthenopia-relieving and eye-moistening composition | |
| JPH0539225A (en) | Medicine for external use | |
| CN102600309A (en) | Traditional Chinese medicine compound preparation for treating acne and seborrheic dermatitis, and preparation method and application of the compound preparation | |
| US11395813B1 (en) | Cannabinoids based pharmaceutical composition | |
| KR101817187B1 (en) | New use of neohesperidin | |
| Muley et al. | FORMULATION AND EVALUATION OF POLYHERBAL EMULGEL FOR MANAGEMENT OF RHEUMATOID ARTHRITIS | |
| CN106138930B (en) | A lotion containing Chinese medicinal effective components for treating ichthyosis, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201117 |